Laying a clear path for incorporating reliable evidence on heterogeneity in value assessments could improve their applicability for healthcare decision making.
Anirban Basu, PhD
Advertisement
Articles by Anirban Basu, PhD
A value-based formulary was implemented that used cost-effectiveness analysis to inform medication co-payments. Diabetes cohort expenditures decreased by $9 per member per month.
Advertisement
Latest Updated Articles
- Impact of a Value-Based Formulary in Three Chronic Disease Cohorts
Published: March 27th 2017 | Updated:
- One Size Does Not Always Fit All in Value Assessment
Published: November 13th 2019 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
3
Boosting RSV Vaccination in Older Adults Could Save Thousands
4
Real-World Data Key to Optimizing CAR T-Cell Therapy Delivery, Outcomes
5
